Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanta Subbarao

Showing results (251-260 of 300) with videos related to

Pageof 30
Sort By:
Nature Medicine|July 15, 2020
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19Jennifer A Juno, Hyon-Xhi Tan, Wen Shi Lee, et al.
ACS Nano|June 27, 2022
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA VaccineYi Ju, Wen Shi Lee, Emily H Pilkington, et al.
The New England Journal of Medicine|June 23, 2021
SARS-CoV-2 Variants and VaccinesPhilip R Krause, Thomas R Fleming, Ira M Longini, et al.
The Journal of Infectious Diseases|February 25, 2016
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody ResponseAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.
The Journal of Infectious Diseases|March 25, 2015
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsBeth D Kirkpatrick, Anna P Durbin, Kristen K Pierce, et al.
JCI Insight|July 12, 2021
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assayEster Lopez, Ebene R Haycroft, Amy Adair, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United StatesAmanda C Perofsky, John Huddleston, Chelsea Hansen, et al.
Nature Communications|February 20, 2021
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19Adam K Wheatley, Jennifer A Juno, Jing J Wang, et al.
Science Signaling|April 25, 2023
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion releaseLarisa I Labzin, Keng Yih Chew, Kathrin Eschke, et al.
Pageof 30

Showing results (251-260 of 300) with videos related to

Sort By:
Pageof 30
Nature Medicine|July 15, 2020
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19Jennifer A Juno, Hyon-Xhi Tan, Wen Shi Lee, et al.
ACS Nano|June 27, 2022
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA VaccineYi Ju, Wen Shi Lee, Emily H Pilkington, et al.
The New England Journal of Medicine|June 23, 2021
SARS-CoV-2 Variants and VaccinesPhilip R Krause, Thomas R Fleming, Ira M Longini, et al.
The Journal of Infectious Diseases|February 25, 2016
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody ResponseAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.
The Journal of Infectious Diseases|March 25, 2015
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsBeth D Kirkpatrick, Anna P Durbin, Kristen K Pierce, et al.
JCI Insight|July 12, 2021
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assayEster Lopez, Ebene R Haycroft, Amy Adair, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United StatesAmanda C Perofsky, John Huddleston, Chelsea Hansen, et al.
Nature Communications|February 20, 2021
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19Adam K Wheatley, Jennifer A Juno, Jing J Wang, et al.
Science Signaling|April 25, 2023
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion releaseLarisa I Labzin, Keng Yih Chew, Kathrin Eschke, et al.
Pageof 30